With AKT being a critical component of the cancer-promoting phosphoinositide 3 kinase-AKT-mammalian target of rapamycin (PI3K-AKT-mTOR) pathway [44], development of inhibitors targeting this pathway could serve as a promising strategy for the inhibition of tumor progression. Here, AKT1 is linked to neoplasm.